培美曲塞治疗肺癌临床疗效观察

Clinical experience of pemetrexed in patients with locally advanced or metastatic non-sma ll cell lung cancer

目的评价培美曲塞治疗复发性晚期肺癌患者的近期疗效及不良反应。方法选择27例经病理学或细胞学确诊的复发性晚期非小细胞肺癌患者,化疗策略:单药:培美曲塞500mg/m2,第1天静脉滴注,每3周重复。联合用药:培美曲塞500mg/m2第1天+卡铂300mg/m2第1天或培美曲塞500mg/m2第1天+顺铂25mg/m2第1～3天,均为每3周重复。结果在27例患者中,无完全缓解患者,部分缓解3例,客观有效率(11.1%),疾病控制率62.9%。结论培美曲塞治疗化疗失败的非小细胞肺癌疗效确切且可耐受。

Objective To observe the safety and efficacy of pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer（NSCLC） after previous chemotherapy.Methods A total of 27 patients with pathologically-confirmed NSCLC were enrolled in this study,Single agent regimen： patients received pemetrexed 500mg/m2 on day 1,by intravenous infusion,with every 21 days.Combination regimen： patients received pemetrexed 500mg/m2 on day 1 and carboplatin 300mg/m2 on day 2 or cisplatin 25mg/m2 on day1～3 by intravenous infusion,with 21 days as one cycle.All patients who received 2 or more cycles could be evaluated.Results 27 patients were evaluable for response and toxicity.The objective response rate was 11.1%（including 0 CR,2 PR）.The disease control rate was 62.9%.The common adverse effects were bone marrow suppression and gast rointestinal toxicity.Cnoclusion Pemetrexed is effective and safe in treating patientswith locally advanced ormetastatic NSCLC after failure of previous chemotherapy